COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0
|
作者：
Petropoulos, A. [1 ]
Cooney, P. [2 ]
Patidar, M. [3 ]
Gudala, K. [3 ]
Tiwari, S. [4 ]
Brennan, R. [2 ]
Kapsogeorgiou, K. [1 ]
Cheilas, G. [1 ]
Banhazi, J. [5 ]
机构：
[1] Novartis Hellas SACI, Athens A1, Greece
[2] Novartis Ireland Ltd, Dublin, Ireland
[3] Novartis Healthcare Private Ltd, Hyderabad, India
[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[5] Novartis Pharma AG, Basel, BS, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [11] Cost-effectiveness analyses of natalizumab (Tysabri®) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK
    Gani, Ray
    Giovannoni, Gavin
    Bates, David
    Kemball, Belinda
    Hughes, Steve
    Kerrigan, John
    PHARMACOECONOMICS, 2008, 26 (07) : 617 - 627
  • [12] Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
    Ray Gani
    Gavin Giovannoni
    David Bates
    Belinda Kemball
    Steve Hughes
    John Kerrigan
    PharmacoEconomics, 2008, 26 : 617 - 627
  • [13] Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature
    Yamamoto, David
    Campbell, Jonathan D.
    AUTOIMMUNE DISEASES, 2012, 2012
  • [14] Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
    Simoens, Steven
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [15] Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population
    Tappenden, Paul
    McCabe, Christopher
    Chilcott, Jim
    Simpson, Emma
    Nixon, Richard
    Madan, Jason
    Fisk, John D.
    Brown, Murray
    VALUE IN HEALTH, 2009, 12 (05) : 657 - 665
  • [16] COST EFFECTIVENESS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
    Mouallif, S.
    Thomas, K.
    Adlard, N. E.
    Cooney, P.
    Blanchette, F.
    Patel, B. P.
    Baharnoori, M.
    Bhan, V
    Clift, F.
    Grima, D.
    VALUE IN HEALTH, 2022, 25 (01) : S63 - S63
  • [17] Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Mouallif, Soukaina
    Thomas, Kim
    Adlard, Nicholas
    Cooney, Philip
    Blanchette, Francois
    Patel, Barkha
    Baharnoori, Moogeh
    Bhan, Virender
    Clift, Fraser
    Grima, Daniel
    NEUROLOGY, 2022, 98 (18)
  • [18] Effectiveness of disease-modifying therapies in relapsing multiple sclerosis in south china
    Tao, V.
    Zhao, L.
    Au, C.
    Ng, A.
    Mok, V.
    Lau, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 531 - 532
  • [19] CLADRIBINE TABLETS (CT) VERSUS OTHER DISEASE-MODIFYING THERAPIES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) - COST-EFFECTIVENESS ANALYSIS.
    Zieiba, P.
    Pawlik, D.
    Wieczorek, J.
    Wojcik, R.
    Kaczor, M. P.
    VALUE IN HEALTH, 2020, 23 : S632 - S632
  • [20] Comparative effectiveness of ublituximab versus other disease-modifying therapies in patients with relapsing multiple sclerosis
    Smith, N.
    Jeyakumar, S.
    Miskin, H.
    Mok, K.
    Mehta, R.
    Beckerman, R.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 579 - 580
12345